Colorectal cancer
Conditions
Interventions
The Drug-sensitive group:Patients were regarded as sensitive to at least one kind of the drug in vitro HDRA assay
The Drug-resistant group:Patients who were diagnosed as resistant to all agents of their chemotherapy regiments in vitro HDRA assay
The Drug-empirical group:Patients who just underwent chemotherapy empirically without the direction of HDRA
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The enrolled patients should possess complete bone marrow function (neutrophils=1.5×10^3/µl, platelets=100×10^3/µl, and Hb=100 g/l), prothrombin time, liver and renal function (serum bilirubin=1.5×upper normal limit, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]=1.5×upper normal limit and serum creatinine=1.5×upper normal limit). ^
Exclusion criteria
Exclusion criteria: (1) history of chemotherapy or radiotherapy before this study; (2) multiple primary tumors; (3) cachexia or important organ dysfunction; (4) history of myocardial infarction or severe unstable angina or congestive heart failure; (5) infectious disease or psychosis; (6) allergy to chemotherapeutic agents; (7) hereditary nonpolyposis CRC and familial adenomatous polyposis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| in vitro-in vivo correlations; | — |
Secondary
| Measure | Time frame |
|---|---|
| the overall survival time (OS);the progression-free survival time(PFS); | — |
Countries
China
Contacts
Public ContactFu Liwu
Sun Yat-sen University Cancer Center
Outcome results
None listed